Sunnyvale, CA, United States of America

Mirko Hennig

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2022-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mirko Hennig: Innovator in Genetic Treatments

Introduction

Mirko Hennig is a prominent inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of genetic treatments, particularly in the area of primary ciliary dyskinesia. With a total of 3 patents to his name, Hennig is recognized for his innovative approaches to medical challenges.

Latest Patents

Hennig's latest patents focus on the treatment of primary ciliary dyskinesia using synthetic messenger RNA. The patents disclose polynucleotides encoding peptides, proteins, enzymes, and functional fragments that can be effectively delivered to organs, such as the lung. These polynucleotides can be expressed within the cells of the organ and are designed to treat diseases or conditions associated with cilia maintenance and function, particularly those involving impaired function of the axoneme, such as DNAI1 or DNAH5.

Career Highlights

Mirko Hennig is currently associated with Transcriptx, Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential to revolutionize treatments for genetic disorders.

Collaborations

Hennig collaborates with notable colleagues, including David J Lockhart and Brandon Alan Wustman. Their combined expertise contributes to the innovative environment at Transcriptx, Inc.

Conclusion

Mirko Hennig stands out as a key figure in the field of genetic treatments, with a focus on addressing complex medical conditions through innovative solutions. His contributions are paving the way for advancements in the treatment of primary ciliary dyskinesia and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…